ExamFinch.com My Study

Study guide

Warfarin & Heparin Reversal

Practice this exam

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

Warfarin & Heparin Reversal

Key Takeaways Explain This Topic AI

Warfarin-associated intracranial bleeding requires prompt current-protocol reversal and repeat INR assessment.

4F-PCC replaces vitamin-K-dependent factors rapidly with less volume than plasma; plasma remains an alternative when PCC is unavailable.

Slow IV vitamin K supports sustained factor synthesis and prevents rebound after transient factor replacement.

Protamine dosing depends on heparin exposure and elapsed time and requires slow administration with adverse-reaction monitoring.

Protamine reverses UFH more completely than LMWH; persistent bleeding requires reassessment of the entire hemostatic problem.

Last updated: October 2026

Warfarin & Heparin Reversal

Anticoagulant-associated intracranial hemorrhage ( I C H ICH I C H ) represents one of the most lethal presentations encountered in the neurointensive care unit. Among patients taking oral vitamin K antagonists ( V K A s VKAs V K A s ) such as warfarin, spontaneous intracerebral hemorrhage carries a 30 -day 30\text{-day} 30 -day mortality rate approaching 40 % to 50 % 40\%\text{ to }50\% 40% to 50% . The clinical trajectory of these patients is dictated by progressive hematoma expansion, which occurs in up to 30 % to 40 % 30\%\text{ to }40\% 30% to 40% of cases and unfolds most aggressively during the first 1 to 4 hours 1\text{ to }4\text{ hours} 1 to 4 hours after symptom onset. Because sustained coagulopathy fuels persistent microvascular bleeding, emergent and complete normalization of the international normalized ratio ( I N R INR I NR ) to ≤ 1.4 \le 1.4 ≤ 1.4 within 1 to 2 hours 1\text{ to }2\text{ hours} 1 to 2 hours of hospital arrival is a paramount neurocritical care quality metric.

Pathophysiology of Warfarin Coagulopathy

Warfarin competitively antagonizes the enzyme vitamin K epoxide reductase complex 1 ( V K O R C 1 VKORC1 V K ORC 1 ), blocking the regeneration of reduced vitamin K (vitamin K hydroquinone). Vitamin K hydroquinone is an indispensable cofactor for the microsomal enzyme γ \gamma γ -glutamyl carboxylase, which converts specific glutamic acid residues into γ \gamma γ -carboxyglutamic acid ( G l a Gla Gl a ) domains on the clotting factors II (prothrombin), VII, IX, and X , as well as natural regulatory proteins C and S . Without these negatively charged G l a Gla Gl a domains, the factors cannot undergo calcium-dependent conformational shifts or bind phospholipid surfaces on activated platelets, completely crippling the extrinsic, intrinsic, and common pathways of the coagulation cascade. Warfarin Coagulation Defect & Factor Half-Lives

  • Factor VII (Extrinsic Pathway): t1/2 ≈ 4-6 hours ── Rapidly depleted; earliest INR prolongation
  • Protein C (Anticoagulant): t1/2 ≈ 8 hours ── Early prothrombotic risk without bridging
  • Factor IX (Intrinsic Pathway): t1/2 ≈ 24 hours
  • Factor X (Common Pathway): t1/2 ≈ 30-40 hours
  • Factor II (Prothrombin): t1/2 ≈ 60-72 hours ── Main driver of sustained thrombin generation
  • Protein S (Anticoagulant): t1/2 ≈ 30 hours

Because the factor half-lives vary substantially, the international normalized ratio reflects the functional decline of Factor VII first, followed by the remaining factors. Reversing this deficit requires immediate exogenous factor replacement coupled with substrate replenishment to restore endogenous hepatic synthesis.

Four-Factor Prothrombin Complex Concentrate (4F-PCC)

Four-Factor Prothrombin Complex Concentrate (e.g., Kcentra) is a virally inactivated, lyophilized concentrate prepared from pooled human plasma. It contains concentrated, non-activated coagulation factors II, VII, IX, and X , alongside the natural anticoagulants Protein C and Protein S , and small amounts of antithrombin and heparin to prevent in-vial thrombogenesis.

Dosing Strategies: Weight/INR-Based vs. Fixed-Dose Protocols

Two validated dosing paradigms exist in neurocritical care practice:

Weight- and Baseline INR-Based Dosing (FDA-Approved): Dosing is calculated using Factor IX units based on actual body weight (capped at 100 kg 100\text{ kg} 100 kg ) and baseline I N R INR I NR :

Baseline I N R 2.0 to 3.9 INR\text{ }2.0\text{ to }3.9 I NR 2.0 to 3.9 : 25 units/kg 25\text{ units/kg} 25 units/kg (maximum dose 2500 units 2500\text{ units} 2500 units )

Baseline I N R 4.0 to 6.0 INR\text{ }4.0\text{ to }6.0 I NR 4.0 to 6.0 : 35 units/kg 35\text{ units/kg} 35 units/kg (maximum dose 3500 units 3500\text{ units} 3500 units )

Baseline I N R > 6.0 INR > 6.0 I NR > 6.0 : 50 units/kg 50\text{ units/kg} 50 units/kg (maximum dose 5000 units 5000\text{ units} 5000 units )

Fixed-Dose Protocols: Many high-volume neurovascular centers utilize a fixed-dose protocol of 1500 to 2000 units 1500\text{ to }2000\text{ units} 1500 to 2000 units IV (or 1000 units 1000\text{ units} 1000 units for I N R < 3.0 INR < 3.0 I NR < 3.0 and 2000 units 2000\text{ units} 2000 units for I N R ≥ 3.0 INR \ge 3.0 I NR ≥ 3.0 ). Fixed dosing eliminates the delays associated with obtaining exact patient weights, avoids complex bedside arithmetic, prevents underdosing in obese individuals, and reduces door-to-needle time by 30 to 60 minutes 30\text{ to }60\text{ minutes} 30 to 60 minutes while demonstrating equivalent rates of successful I N R INR I NR normalization ( ≤ 1.4 \le 1.4 ≤ 1.4 ) and hematoma containment.

Onset and Kinetics

Unlike blood components that require thawing, 4F-PCC reconstitutes in a modest volume ( 80 to 100 mL 80\text{ to }100\text{ mL} 80 to 100 mL ) and can be infused rapidly at up to 8.4 units/kg/min 8.4\text{ units/kg/min} 8.4 units/kg/min . It achieves complete I N R INR I NR correction within 10 to 15 minutes 10\text{ to }15\text{ minutes} 10 to 15 minutes following completion of the infusion, arresting active microvascular extravasation during the golden window of hematoma expansion.

Mandatory Co-Administration of Intravenous Vitamin K

A critical pharmacological principle governing 4F-PCC therapy is its transient therapeutic window. Exogenous Factor VII has an intravascular half-life of only 4 to 6 hours 4\text{ to }6\text{ hours} 4 to 6 hours . Once the infused Factor VII is consumed and cleared, the patient will experience rebound coagulopathy ( I N R INR I NR re-elevating to > 1.5 – 2.0 > 1.5\text{--}2.0 > 1.5 – 2.0 ) at 12 to 24 hours 12\text{ to }24\text{ hours} 12 to 24 hours if endogenous factor production is not restored. 4F-PCC + Vitamin K Synergy Timeline

  • 0 Hours: 4F-PCC infused ── Exogenous Factor VII/IX/X/II flood circulation ── INR drops to ≤ 1.4 in 15 min
  • 2-6 Hours: Endogenous hepatic synthesis begins via IV Vitamin K (phytonadione)
  • 6-12 Hours: Exogenous Factor VII degrades (t1/2 ≈ 6 h) ── Endogenous factors replace cleared proteins
  • 12-24 Hours: Hemostasis sustained ── Rebound coagulopathy successfully averted
  • Phytonadione Protocol & Administration Safety

Dose & Route: Phytonadione 10 mg 10\text{ mg} 10 mg slow IV infusion , diluted in 50 mL 50\text{ mL} 50 mL of normal saline or 5 % 5\% 5% dextrose in water, administered over 30 minutes 30\text{ minutes} 30 minutes .

Black Box Warning & Anaphylactoid Reactions: Rapid intravenous push of phytonadione can trigger fatal anaphylactoid shock, profound systemic hypotension, bronchospasm, and cardiac arrest mediated by the polyoxyethylated castor oil solubilizers. Slow infusion over 30 minutes minimizes this risk.

Inadequacy of Alternative Routes: Subcutaneous vitamin K exhibits erratic, delayed, and unpredictable bioavailability due to local tissue vasoconstriction and variable lymphatic uptake. Oral vitamin K requires 12 to 24 hours 12\text{ to }24\text{ hours} 12 to 24 hours to lower the I N R INR I NR and cannot be reliably administered to dysphagic, intubated, or obtunded neuro-ICU patients.

Warning

Never administer 4F-PCC as monotherapy for warfarin reversal! Exogenous factor concentrates only bridge the initial 6 to 8 hours 6\text{ to }8\text{ hours} 6 to 8 hours . Intravenous vitamin K ( 10 mg 10\text{ mg} 10 mg in 50 mL 50\text{ mL} 50 mL over 30 minutes) must be ordered and administered concurrently at presentation to sustain factor levels beyond 12 hours.

Fresh Frozen Plasma (FFP): Why It Is Inferior

Historically, Fresh Frozen Plasma was the mainstay of warfarin reversal. Contemporary neurocritical care guidelines (AHA/ASA Class I, Level of Evidence A) strictly relegate FFP to a secondary salvage option reserved only for settings where 4F-PCC is unobtainable.

Clinical Characteristic Four-Factor PCC (Kcentra) Fresh Frozen Plasma (FFP)

Time to INR Normalization 10 to 15 minutes 10\text{ to }15\text{ minutes} 10 to 15 minutes post-infusion 6 to 12 hours 6\text{ to }12\text{ hours} 6 to 12 hours (delayed by thawing and slow infusion)

Volume Burden Small volume ( 80 – 100 mL 80\text{--}100\text{ mL} 80 – 100 mL ) Massive volume ( 15 to 30 mL/kg 15\text{ to }30\text{ mL/kg} 15 to 30 mL/kg , ≈ 1.5 – 2.5 L \approx 1.5\text{--}2.5\text{ L} ≈ 1.5 – 2.5 L )

  • Pulmonary Complications Minimal risk High risk of TACO ( 10 % – 15 % 10\%\text{--}15\% 10% – 15% ) and TRALI
  • ABO Crossmatching Not required (universal compatibility) Mandatory ABO blood group compatibility testing

Efficacy in Severe Coagulopathy Reliably corrects I N R INR I NR even when baseline > 10 > 10 > 10 Inherent FFP I N R INR I NR is ≈ 1.2 – 1.3 \approx 1.2\text{--}1.3 ≈ 1.2 – 1.3 ; dilutional plateau prevents normalization below 1.4 1.4 1.4

Trial Evidence (INCH Trial) Significantly lower 24 h 24\text{ h} 24 h hematoma expansion ( 19 % 19\% 19% ) High rate of 24 h 24\text{ h} 24 h hematoma expansion ( 35 % 35\% 35% )

In acute brain injury, infusing 2 liters 2\text{ liters} 2 liters of plasma raises central venous pressure, impairs internal jugular cerebral venous drainage, provokes acute hydrostatic pulmonary edema, and precipitates surges in intracranial pressure ( I C P ICP I CP ).

Heparin Reversal: Unfractionated Heparin & LMWH

Acute bleeding in patients receiving intravenous unfractionated heparin ( U F H UFH U F H ) or subcutaneous low-molecular-weight heparin ( L M W H LMWH L M W H , enoxaparin) requires rapid neutralization with protamine sulfate , a strongly basic, polycationic peptide derived from salmon sperm that electrostatically complexes with strongly acidic polyanionic heparin chains to form a stable, inactive salt.

Unfractionated Heparin (UFH) Reversal

Because intravenous unfractionated heparin has a short plasma elimination half-life ( t 1 / 2 ≈ 60 – 90 minutes t_{1/2} \approx 60\text{--}90\text{ minutes} t 1/2 ​ ≈ 60 – 90 minutes ), protamine dosing is tailored to the amount of heparin delivered in the preceding 2 to 3 hours 2\text{ to }3\text{ hours} 2 to 3 hours :

Dosing Formula: 1 mg 1\text{ mg} 1 mg protamine sulfate per 100 units 100\text{ units} 100 units of UFH administered in the prior 2 to 3 hours.

Adjustment for Infusion Halting: If the heparin infusion was stopped 30 to 60 minutes 30\text{ to }60\text{ minutes} 30 to 60 minutes prior, administer 0.5 to 0.75 mg 0.5\text{ to }0.75\text{ mg} 0.5 to 0.75 mg per 100 units. If stopped > 2 hours > 2\text{ hours} > 2 hours prior, administer 0.25 to 0.5 mg 0.25\text{ to }0.5\text{ mg} 0.25 to 0.5 mg per 100 units.

Maximum Single Dose: Capped strictly at 50 mg 50\text{ mg} 50 mg IV .

Warning

Administration Hazards & Protamine Toxicity: Rapid intravenous push of protamine triggers catastrophic histamine release, pulmonary vasoconstriction, acute right ventricular failure, and profound systemic hypotension. Infuse protamine slowly over at least 10 minutes 10\text{ minutes} 10 minutes (rate ≤ 5 mg/min \le 5\text{ mg/min} ≤ 5 mg/min ). Furthermore, excessive protamine doses exert intrinsic anticoagulant effects by binding platelets and inhibiting thrombin generation; never exceed 50 mg 50\text{ mg} 50 mg per single dose.

Low Molecular Weight Heparin (Enoxaparin) Reversal

Reversing enoxaparin is pharmacologically constrained because protamine only neutralizes the larger heparin fragments containing the antithrombin-binding pentasaccharide sequence:

Timing < 8 Hours < 8\text{ Hours} < 8 Hours : If enoxaparin was administered within the past 8 hours, give 1 mg 1\text{ mg} 1 mg protamine per 1 mg 1\text{ mg} 1 mg enoxaparin (max 50 mg 50\text{ mg} 50 mg ). A second dose of 0.5 mg 0.5\text{ mg} 0.5 mg protamine per 1 mg 1\text{ mg} 1 mg enoxaparin may be repeated in 2 to 4 hours 2\text{ to }4\text{ hours} 2 to 4 hours if bleeding persists.

Timing 8 to 12 Hours 8\text{ to }12\text{ Hours} 8 to 12 Hours : Administer 0.5 mg 0.5\text{ mg} 0.5 mg protamine per 1 mg 1\text{ mg} 1 mg enoxaparin .

Timing > 12 Hours > 12\text{ Hours} > 12 Hours : Protamine is generally withheld unless severe renal failure ( C r C l < 30 mL/min CrCl < 30\text{ mL/min} C r Cl < 30 mL/min ) prolongs enoxaparin clearance.

Incomplete Anti-Xa Clearance: Protamine completely neutralizes the anti-IIa (thrombin) activity of enoxaparin, but achieves only 60 % to 75 % 60\%\text{ to }75\% 60% to 75% neutralization of anti-factor Xa activity . In refractory, life-threatening intracranial hemorrhage, off-label pro-hemostatic bypass with 4F-PCC ( 50 units/kg 50\text{ units/kg} 50 units/kg ) or recombinant activated factor VII ( r F V I I a rFVIIa r F V II a , 90 μ g/kg 90\text{ }\mu\text{g/kg} 90 μ g/kg ) may be considered.